^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dexanabinol (ETS2101)

    i
    Other names: ETS2101, HU-211, PRS-211007, PRS 211007, PA-50211, PA 50211
    Associations

    News

    Trials
    Company:
    Ceska Lekarnicka, e-therap
    Drug class:
    TNFα inhibitor, NF-κB inhibitor, COX2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping. (PubMed, J Gastrointest Surg)
    Using available genetic atlas data, potential drug candidates for treatment of pNETs were identified based on differentially expressed genes. These results may help focus efforts on identifying targeted agents with therapeutic efficacy to treat patients with pNETs.
    Journal • Gene Signature
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL20 (C-C Motif Chemokine Ligand 20) • GNG4 (G Protein Subunit Gamma 4) • LEP (Leptin)
    |
    erlotinib • azacitidine • canertinib (CI-1033) • dexanabinol (ETS2101)
    over2years
    Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. (PubMed, Front Pharmacol)
    Dexanabinol failed to restore bortezomib-induced decreases in electrophysiological endpoints in rats, and it did not compromise bortezomib anti-cancer effects in U266 multiple myeloma cells and a murine xenograft model. Owing to its favorable safety profile in humans and preclinical efficacy, dexanabinol might represent a treatment option for bortezomib-induced neuropathic pain.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    bortezomib • dexanabinol (ETS2101)